Phaseline

Companies › BrYet US

BrYet US: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ML-016
pH-sensitive polymeric doxorubicin formulated in a nanoporous silicon microparticle
–Phase 1Advanced Solid Tumor With Lung and/or Liver InvolvementOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07723482ML-016Phase 1Advanced Solid Tumor With Lung and/or Liver InvolvementOncologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.